Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management (vol 15, 1507840, 2025)

초록

Breast Cancer In the published article, there was a mistake in the text and citation in Section 4.4. “HER2-negative metastatic BC carrying BRCA germline pathogenic variant”. In paragraph 1 of the section 4.4, the following text and citation was incorrect “The phase III OlympiAD trial confirmed the effectiveness of olaparib in individuals with hereditary BRCA germline pathogenic variants and HER2-negative mBC, with a statistically significant improvement in progression-free survival and OS compared with the physician’s choice of CT treatment (Table 4) (48). The 4-year OS in the olaparib group was 89·8% compared with 86·4% in the placebo group (9).” The correct text and citation should be: “The phase III OlympiAD trial confirmed the effectiveness of olaparib in individuals with hereditary BRCA germline pathogenic variants and HER2-negative mBC, with a statistically significant improvement in progression-free survival compared with the physician’s choice of CT treatment (Table 4) (46). The median final OS was 19.3 months with olaparib and 17.1 months with the physician’s choice of CT, which was comparable between the two groups (48).” The original version of this article has been updated.

키워드